Join
Live feed
·
PRReleasevia Quantisnow
AzurRx BioPharma, Inc. logo

AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency (EPI)

ByQuantisnow·Wall Street's wire, on your screen.
AZRX· AzurRx BioPharma, Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AZRX (AzurRx BioPharma, Inc.) and more on Quantisnow.